Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by CoreCap Advisors LLC

CoreCap Advisors LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 36.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,831 shares of the biopharmaceutical company's stock after acquiring an additional 4,242 shares during the period. CoreCap Advisors LLC's holdings in Halozyme Therapeutics were worth $757,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics in the fourth quarter worth about $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics in the fourth quarter worth about $29,000. Smartleaf Asset Management LLC grew its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust grew its holdings in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 322 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded up $1.53 during midday trading on Thursday, reaching $49.44. The company had a trading volume of 1,793,179 shares, compared to its average volume of 1,581,854. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The business's 50-day simple moving average is $61.13 and its 200 day simple moving average is $55.91. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $70.51. The stock has a market cap of $6.09 billion, a P/E ratio of 14.44, a P/E/G ratio of 0.42 and a beta of 1.26.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $264.86 million for the quarter, compared to analysts' expectations of $231.21 million. During the same quarter last year, the company earned $0.79 EPS. The business's revenue was up 35.2% on a year-over-year basis. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now owns 28,611 shares in the company, valued at $1,727,246.07. The trade was a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,697 shares of company stock valued at $1,276,552 over the last 90 days. Corporate insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on HALO shares. Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price target for the company from $73.00 to $62.00 in a report on Wednesday. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 target price on the stock. in a report on Tuesday. Finally, Leerink Partnrs cut shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $61.90.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.